ES2033426T3 - Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina. - Google Patents

Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.

Info

Publication number
ES2033426T3
ES2033426T3 ES198888302657T ES88302657T ES2033426T3 ES 2033426 T3 ES2033426 T3 ES 2033426T3 ES 198888302657 T ES198888302657 T ES 198888302657T ES 88302657 T ES88302657 T ES 88302657T ES 2033426 T3 ES2033426 T3 ES 2033426T3
Authority
ES
Spain
Prior art keywords
controlled release
deoxytimidine
azido
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888302657T
Other languages
English (en)
Inventor
Harry Phillip Jones
Robert Judson Mackey
Michael John Desmond Gamlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2033426T3 publication Critical patent/ES2033426T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A FORMULACIONES FARMACEUTICAS QUE COMPRENDEN UNIDADES DISCRETAS DE ZIDOVIDINA PROPORCIONADAS CON UN RECUBRIMIENTO DE LIBERACION CONTROLADO EN EL QUE DICHAS UNIDADES ESTAS PREFERIBLEMENTE EN FORMA DE ESFEROIDES.
ES198888302657T 1987-03-27 1988-03-25 Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina. Expired - Lifetime ES2033426T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878707421A GB8707421D0 (en) 1987-03-27 1987-03-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2033426T3 true ES2033426T3 (es) 1993-03-16

Family

ID=10614823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888302657T Expired - Lifetime ES2033426T3 (es) 1987-03-27 1988-03-25 Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.

Country Status (17)

Country Link
US (1) US4917900A (es)
EP (1) EP0284407B1 (es)
JP (1) JP2719344B2 (es)
KR (1) KR960013434B1 (es)
AT (1) ATE63818T1 (es)
AU (1) AU607474B2 (es)
CA (1) CA1308026C (es)
DE (1) DE3862974D1 (es)
DK (1) DK175348B1 (es)
ES (1) ES2033426T3 (es)
GB (1) GB8707421D0 (es)
GR (1) GR3002030T3 (es)
IE (1) IE60605B1 (es)
IL (1) IL85870A (es)
NZ (1) NZ224026A (es)
PT (1) PT87081B (es)
ZA (1) ZA882168B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US4938966A (en) * 1988-11-30 1990-07-03 Riker Laboratories, Inc. Controlled release flecainide acetate formulation
GB8912420D0 (en) 1989-05-31 1989-07-19 Schram Cornelius J Ultrasonic systems
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE69208636T2 (de) * 1991-06-21 1996-07-11 Acic Canada Inc Verfahren zur herstellung von zidovudine
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
EP0654038B1 (en) * 1992-08-04 1999-11-10 James M. Dunn Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
BR0109602A (pt) * 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
KR101022541B1 (ko) * 2002-06-24 2011-03-16 가부시키가이샤 아데카 난연제 조성물 및 이 조성물을 함유한 난연성 수지 조성물
AU2003291457A1 (en) * 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
US20070231385A1 (en) * 2003-10-01 2007-10-04 Lupin Limited Controlled Release Pharmaceutical Composition and a Process for Preparing the Same
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2178518A2 (en) * 2007-07-13 2010-04-28 Bend Research, Inc Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
CN106333957A (zh) * 2016-08-19 2017-01-18 丁静 齐多夫定用于制备自身免疫性神经炎治疗药物的应用
WO2019038430A1 (en) * 2017-08-25 2019-02-28 Eleonor Sprl COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERIN ALKALOID AND METHOD FOR PRODUCING THE SAME

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE145365C (es) *
BE785702A (fr) * 1971-07-14 1972-10-16 Roehm Gmbh Produits de revetement de formes medicamenteuses et leur utilisation
BE787973A (fr) * 1971-09-04 1973-02-26 Beecham Group Ltd Comprimes pharmaceutiques a effet retard
ES438635A1 (es) * 1974-06-24 1977-02-16 Shinetsu Chemical Co Procedimiento para el revestimiento de moldes solidos de do-sificacion.
DE3170764D1 (en) * 1980-11-12 1985-07-04 Ciba Geigy Ag Fast disaggregating pharmaceutical tablet
EP0052075A1 (de) * 1980-11-12 1982-05-19 Ciba-Geigy Ag Körnige Arzneimittel-Retardform
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
IT1168014B (it) * 1981-08-05 1987-05-20 Erba Farmitalia Forme farmaceutiche a cessione protratta
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
JPS59227817A (ja) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd 持続性経口用ブレデニン製剤
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
GB8506869D0 (en) * 1985-03-16 1985-04-17 Wellcome Found Antiviral compound
IE73219B1 (en) * 1985-03-16 1997-05-07 Wellcome Found Therapeutic nucleosides
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3650130T3 (de) * 1985-03-16 2003-07-24 The Wellcome Foundation Ltd., London Antivirale Nukleoside.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB2209669B (en) * 1987-09-11 1992-02-12 Squibb & Sons Inc Pharmaceutical composition containing high drug load and method for preparing same

Also Published As

Publication number Publication date
US4917900A (en) 1990-04-17
CA1308026C (en) 1992-09-29
AU607474B2 (en) 1991-03-07
GB8707421D0 (en) 1987-04-29
IL85870A (en) 1992-02-16
KR960013434B1 (ko) 1996-10-05
DE3862974D1 (de) 1991-07-04
KR880010759A (ko) 1988-10-24
JPS63255230A (ja) 1988-10-21
ZA882168B (en) 1989-11-29
EP0284407A3 (en) 1988-12-14
PT87081A (pt) 1988-04-01
PT87081B (pt) 1992-07-31
NZ224026A (en) 1991-03-26
DK175348B1 (da) 2004-09-06
EP0284407B1 (en) 1991-05-29
IE60605B1 (en) 1994-07-27
DK164388A (da) 1988-09-28
EP0284407A2 (en) 1988-09-28
JP2719344B2 (ja) 1998-02-25
IE880899L (en) 1988-09-27
AU1375688A (en) 1988-09-29
DK164388D0 (da) 1988-03-25
GR3002030T3 (en) 1992-12-30
ATE63818T1 (de) 1991-06-15

Similar Documents

Publication Publication Date Title
PT87081A (pt) Controlled release formulations
ES2099145T3 (es) Heparosanos n,o-sulfatados, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
ES2036194T3 (es) Derivados n-fosfonilmetoxialquilicos de bases de pirimidina y purina, metodos para su preparacion y composiciones farmaceuticas basadas en ellos, con actividad antivirica.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
GR1000392B (el) Σταθεροποιημενες συνθεσεις περιεχουσες επιδερμικο παραγοντα αναπτυξης.
ES2059377T3 (es) Pirazoles 1,5-diaril-3-sustituidos farmacologicamente activos y procedimiento para sintetizar los mismos.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
ES2027005T3 (es) Procedimiento para preparar una formulacion farmaceutica de liberacion controlada de acrivastina.
ES2061559T3 (es) Triazolinonas substituidas.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES502080A0 (es) Procedimiento para la preparacion de composiciones fosfoli- pidicas de colina
MX9300584A (es) Mezcla de oligosacaridos sulfatados, procedimiento para su preparacion y composicion farmaceutica que la contiene.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2122221T3 (es) Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2052622T3 (es) Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos.
MX6274E (es) Procedimiento para la preparacion de composiciones parmaceuticas que contienen alcohilantes citostaticos destoxificados
ES2158309T3 (es) Fenilamidinas sustituidas, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.
ZA935718B (en) Liponucleotides of seco-nucleosides and pharmaceutical compositions with antiviral action containing them
ES2054887T3 (es) Nuevos 5-halogeno-tienoisotiazol-3(2h)-on-1,1-dioxidos basicamente substituidos, un procedimiento para su obtencion y los preparados farmaceuticos que contienen estos compuestos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 284407

Country of ref document: ES